In the United States, it’s estimated that 1 to 3 million Americans live with postural orthostatic tachycardia syndrome, or POTS, a common form of dysautonomia.
With the recent COVID-19 pandemic, we are seeing a major increase in POTS cases as many with Long COVID meet the diagnostic criteria for POTS or other forms of dysautonomia.
RTHM connects patients to treatment options from home.
RTHM provides prescription access to a variety of medications for Long COVID, ME/CFS, POTS and MCAS
Pyridostigmine improves autonomic function, particularly in patients experiencing dysautonomia.
A beta-blocker that helps manage symptoms related to dysautonomia, such as elevated heart rate and anxiety.
By constricting blood vessels and increasing blood pressure, midodrine reduces dizziness and improves daily functioning.
Lowers heart rate without affecting blood pressure, making it ideal for patients with autonomic issues like postural orthostatic tachycardia syndrome (POTS).
Not sure which treatment might be right for POTS? Start with RTHM at no cost.
Our free intelligence platform builds a personalized Health Roadmap based on your history, symptoms, and health records—helping highlight which treatments or labs may be most relevant to your case.
@potszebra
"I lost years of my life feeling like I needed a heart transplant. My doctors told me there wasn't a medication that treated POTS and I actually believed them! Until I found RTHM."
"RTHM has been a huge lifeline in a maze of finding out what's happening to my life with Long COVID and effective treatments for such complex, new issues."
"RTHM is peak healthcare and should be used as a blueprint for a new standard of care all over. Thank you for saving me."